Vera Therapeutics stockholders elect three Class II directors, ratify KPMG, approve say-on-pay

Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The final voting results are as follows: For Against Abstain 61,834,842 44,710 87,298

Proposal 1– Election of Directors. The Company’s stockholders elected the three persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Michael M. Morrisey, Ph.D. 45,288,710 13,814,671 2,863,469 Patrick G. Enright 54,697,296 4,406,085 2,863,469 James R. Meyers 58,946,269 157,112 2,863,469

Proposal 3 – Advisory Vote on Executive Compensation. The Company’s stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows: For Against Abstain Broker Non-Votes 56,585,568 2,433,537 84,276 2,863,469